Medikamenters nevroprotektive virkning på Parkinson sykdom

Abstract

Objective: Parkinson’s disease (Parkinson’s disease) is a progressive neurological disorder characterised by a large number of motor and non-motor features that can impact on function to a variable degree. This review evaluates the early treatment of patients afflicted with Parkinson’s disease, to determine the disease modifying effect therapy has.

Background information was found in textbooks, and articles received from our supervisor. A nonspecific search was executed in PUBMED.

Results: Levodopa has been associated with wearing-off and dyskinesis, however, producing beneficial symptom relief. Therapy with dopamine agonists or the mono-amine oxidase type B inhibitor, rasagiline (1 mg), have a reduction in adverse motor side-effects compared to levodopa, but they also have a less symptomatic relief than levodopa, and have other adverse effects like hallucinations.

Conclusions: We concur with current treatment, in that a higher quality of life is achieved when elderly patients and those afflicted with crippling symptoms start initial treatment with levodopa. Younger healthy patients have more benefits from initial administration of dopamine agonists, or rasagiline 1 mg who are expected to live longer and require predictable motor functions.